SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The growth was driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system, reaching 30 systems during the quarter. Gross profit increased 20% to $7.1 million, with a gross margin of 50.9%. The company reported a net loss of $2.7 million, or $0.01 per diluted share, compared with a net loss of $0.3 million in the prior-year quarter.
For the first half of 2026, revenue surged 65.6% to $25 million, and SSi Mantra installations rose 47.4% to 56 systems. As of June 30, SS Innovations held $13.6 million in cash and cash equivalents, with no long-term debt. The cumulative installed base reached 224 SSi Mantra systems across 12 countries. The company also reported 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. Notably, SS Innovations completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration (FDA) to complete its review of the company’s 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. Additionally, the company believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones could significantly expand the market for SS Innovations’ surgical robotic systems, which are designed to make robotic surgery more affordable and accessible globally.
The company’s product portfolio includes the SSi Mantra surgical robotic system and the SSi Mudra surgical instruments, which support procedures including cardiac surgery. SS Innovations, an American company headquartered in India, plans to expand its global presence with its user-friendly and cost-effective robotic solutions.
Investors and industry observers will be watching for further developments as the company continues to grow its installed base and advances through regulatory processes. The financial results and operational updates were detailed in the company’s press release, which is available at https://ibn.fm/nTMso. For more information on the company and its latest news, visit its newsroom at https://ibn.fm/SSII.
